Among Swedish memory-clinic patients without dementia, more stressful life events were linked to a spinal-fluid sign of Alzheimer’s amyloid buildup, but only in people with moderate-to-high insomnia symptoms, according to a 2026 study.1 Research Highlights Stress and insomnia worked together: in 103 patients with spinal-fluid tests, lifetime stressful events and insomnia symptoms interacted in relation …
In APP/PS1 Alzheimer's model mice, deleting PTP1B or treating with the allosteric inhibitor DPM-1003 improved memory behavior, lowered amyloid burden, and pushed microglia toward SYK-driven clearance — a plausible mechanism, not a human treatment result yet.1 Research Highlights PTP1B loss improved behavior in APP/PS1 mice. Genetic deletion and DPM-1003 treatment improved novel object recognition and …
A 2026 Nature Neuroscience study found that lecanemab cleared amyloid in a humanized-microglia Alzheimer’s disease model only when microglia and the antibody’s intact Fc fragment were both present: X-34 plaque area differed across IgG1, lecanemab, and Fc-silenced LALA-PG groups (P = 0.0003), 82E1 plaque area differed across groups (P < 0.0001), and microglia-deficient mice showed …